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PRACTICAL APPLICATION
A training paradigm to enhance performance and
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Training has been important to facilitate the safe use of new devices designed to repair vascular structures. This
paper outlines the generic elements of a training program for vascular devices and uses as an example
the actual training requirements for a novel device developed for the treatment of bifurcation intracranial
aneurysms. Critical elements of the program include awareness of the clinical problem, technical features
of device, case selection, and use of a simulator. Formal proctoring, evaluation of the training, and recording the
clinical outcomes complement these elements. Interventional physicians should embrace the merits of a training
module to improve the user experience, and vendors, physicians, and patients alike should be aligned in the goal
of device training to improve its success rate and minimize complications of the procedure.
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S
ince the onset of endovascular intervention in the
late 1970s, training has been important for the safe
and effective use of new devices that were developed
to facilitate the return of diseased (congenitally or acquired)
or damaged vascular structures to a more normal physiologic
state. Adequacy of this training frequently is the difference
between success and failure and, more importantly, freedom
from complication in endovascular endeavors. As newer
endovascular devices become more complex, sophisticated,
and innovative, training in their appropriate application and
use is even more important. Large government regulatory
and nongovernment bodies such as the U.S. Food and Drug
Administration (FDA) and the World Health Organization
(WHO) have recognized the dilemma of the mismatch
between the profusion of medical devices and capacity of
the end user to assimilate the information necessary for the
proper use of new devices. In particular, training in the
nuances of the use of catheter-based technologies becomes
even more important as endovascular medicine becomes
predominant over surgical intervention in some fields (1, 2).
Although catheter-based diagnostic procedures have
existed since the 1930s, with the pioneering experiments
of Forssmann and Cournand (3), coaxial catheter-wire
techniques were not developed until the 1980s to enable
interventional procedures (4). These techniques allowed
safe and effective navigation of a microcatheter passed
through a guiding catheter and over a guide wire to a site
of vascular disease, with the aim of avascular intervention,
in this first instance, balloon angioplasty. And it was
not long before triaxial catheter systems (a tube within a
tube within a tube, the smallest, in turn, being advanced
over a wire) were used to reach deeper and more selectively
into the vascular system. Although the fastest growth and
greatest application of these techniques initially occurred
in the coronary vascular field to deliver devices such as
balloons and stents to improve outcomes, these techniques
are now extensively used throughout the vascular tree,
not only to deliver devices to facilitate repair of blood
vessels, per se, but also for correction of congenital and
acquired cardiac defects, valvular disorders, for delivery
of chemotherapeutic agents, nanoparticles, glues, and
thrombolytic drugs (511).
Objective
This paper outlines the generic elements of a training
program for vascular devices and uses as an example the
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actual training requirements for a novel device developed
for the treatment of intracranial aneurysms occurring at
bifurcations, the eCLIPs device (Evasc Medical Systems
Corp., Vancouver, BC, Canada) (12).
Methods
Elements of training
Awareness of the clinical problem
Training on the use of a device begins with awareness of
the clinical problem for which the device is developed to
manage. Bifurcation intracranial aneurysms are a major
source of morbidity and mortality. Sixty-four percent of
all cerebral aneurysms occur at arterial bifurcations (13).
Worldwide prevalence of unruptured intracranial aneur-
ysm is 3.2% in the general population, but this number
may be higher in females, older patients, and patients
with an affected family history or certain genetic condi-
tions (14). A systematic review of all reports on pre-
valence of intracranial aneurysms concluded that rupture
occurs in 12% of all intracranial aneurysms per year and
results in a subarachnoid hemorrhage (15). This hemor-
rhage may be life-threatening, with a mortality rate of
2550%, or it may cause significant cognitive, physical,
and/or psychological disabilities in nearly 50% of the
survivors, entailing a considerable impact on their quality
of life (16). The eCLIPs device was developed to address
the most complex subset of this disease.
Technical features of device: alignment with the anatomy
of the clinical problem
The next step is to confirm that the design of the device and
the expected benefits of the design elements will address
the clinical problem. The functional attributes of the
eCLIPs device depend on a spine-rib design (Fig. 1) that
cannot shorten upon deployment; an anchor segment
that provides stability of the device in situ; and a dense
leaf segment that bridges the neck of the aneurysm to
allow for coil retention, flow disruption away from the
aneurysm sac, and endothelial growth. The device can be
safely retracted back into the microcatheter and reposi-
tioned or removed before detachment. All these features
combine to produce healing of the aneurysm to return the
bifurcation to its original physiologic state: the device is
fully incorporated into the vessel wall, leaving no metal
in either the main vessel or side branches, exteriorizes the
aneurysm from the circulation, and does not impede access
to side branches. Hence, the eCLIPs device allows for
physiologic remodeling of the bifurcation aneurysm (12).
Reviewing the device’s indications for use (IFU), as
determined by various regulatory bodies (e.g., CE Mark),
is a requirement before choosing the device. Important in
the analysis of the use of a new device is the comparison
of its design elements against those of current technolo-
gies developed for similar indications. By this process, the
interventional physician will have a better understanding
of the pros and cons of using various technologies in
specific situations.
Evasc’s training program presents each eCLIPs pro-
duct to the physician with a discussion of the product’s
description, the specific function accruing to each of the
design features, and its IFU.
A laminated image set, ‘eCLIPs Introduction Images’,
illustrates the eCLIPs treatment concept compared to
other technologies.
Case selection
Having identified the clinical problem, the need for a
solution, and recognition that the proposed device has
design features that can provide a functional solution to
the problem, the next step is selection of a case to be
managed by the device. Although the interventionalist may
use the foregoing process to make an informed decision to
use the device in a chosen case, communication with
mentors and other colleagues, clinical specialists employed
by the device’s vendors, and even use of an interactive App
(e.g., eCLIPs MD, Apple Store) may be effective methods
to refine case selection and avoid inappropriate cases,
especially early in the interventionalist’s experience with
the device.
Use of simulator
Hands-on experience with a system model that simulates
clinical anatomy, with options for a variety of anatomic
models that illustrate a spectrum of anatomic variations
should be a prerequisite to clinical use in the laboratory.
A well-constructed model (Fig. 2), using live video rather
Section B-B Section A-A
Flow Disrupting
Leaf Segment
Anchor
Segment
Fig. 1. eCLIPs device: three-dimensional view (left), side view (middle), plan view (right).
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than radiographic imaging, can usually supplant the
need for trialing the device in an animal model that is
expensive, wasteful, and contrary to environmental and
animal protection mores. A simulation model is compact,
mobile, can be erected in minutes, and uses custom-made
aneurysm models that can be constructed to mimic the
precise anatomy of a planned case.
In Evasc’s hands-on demonstration, the trainee uses
the system model setup to deliver, deploy, position, and
then detach an eCLIPs device while following the eCLIPs
product’s IFU. This simulated use training is performed
under the direction of the trainer, either a physician or a
clinical specialist. There is also an animated demonstra-
tion of how the eCLIPs device is deployed (Fig. 3) and
how the other products (catheter, detacher) work.
During this simulated use training, the trainer refers
to the eCLIPs Simulated Use Training Checklist section
of the Physician Training Form so that documentation
exists at each step.
Clinical procedural aspects
Proctoring
After becoming versed in the use of the device in a
simulator, if feasible the next step should be for the trainee
to attend a proctor’s case as an observer. The trainee is
encouraged to share several possible cases with the proctor
for discussion of lesion suitability. This is best achieved at
the original session to allow interactive learning, but it can
occur any time afterward. Also, if feasible in a short time
thereafter the trainee should proceed with a case (having
discussed case selection, reviewed the simulator experi-
ence, and gained the usual patient consent). The clinical
specialist and a proctor should attend the case, the former
to provide a refresher to the simulator experience imme-
diately before the case and the latter to provide detailed
procedural nuances as the case proceeds.
Device-related procedural details
Each device and its delivery and detachment mechanisms
will be more or less unique to the device, and even after
review in a simulator they should require attention to
detail during the procedure.
Evasc’s training for eCLIPs introduces the hypotube of
the delivery portion of the eCLIPs device and how to use
a mobile wire through the hypotube. During preparation,
the focus is on the following (12): exposing the device
once situated in a branch vessel (Fig. 3a and b); obtaining
second branch access (Fig. 3c); confirmation of correct
1 – Setup of Deployment 2 – Setup Webcam stand:
3 – Final Assembly: 4 – Video Image of Aneurysm model:
Fig. 2. Illustrations of benchtop setup of aneurysm model simulator.
(a) (b) (c) (d) (e) (f)
Fig. 3. Animated eCLIPS deployment sequence.
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orientation of device, retracting device into the sheath
as necessary, and review orientating and positioning
(Fig. 3d); and detachment and subsequent coiling, as
necessary (Fig. 3e and f).
Evaluation of training
Evaluating the training by choosing prespecified outcomes
that satisfy the training goals is important in the whole
process of device training. These may be categorized as
follows:
1) Proctor adjudication of case selection, procedural
strategy, adherence to procedural strategy, and com-
pliance with IFU.
2) Outcome of device deployment elements, including
successful guide wire placement and use as a rail in the
triaxial system; success of delivery catheter (micro-
catheter) placement; precision of device placement
(axial and rotational alignment); and adjuvant coiling
if necessary.
3) Procedural outcome is evaluated by a combination
of successful deployment, successful coiling, angio-
graphic evaluation of outcome, and absence of
complications.
4) Finally, it is important to record data and critical
elements of the procedure and outcome for quality
review and comparison with the use of other
technologies.
Evasc Medical has designed its physician training
program for the eCLIPs products to meet the follow-
ing objectives:
a. Understand the purpose of each eCLIPs product
b. Obtain experience with the eCLIPs product
through a simulated use training model
c. Obtain experience with the eCLIPs product
through proctored clinical cases
A physician is considered trained on the eCLIPs product
once the first two objectives have been met and the first few
clinical cases are performed with a proctor. It is recom-
mended that the first five clinical cases using the eCLIPs
product be proctored by a physician designated by Evasc;
however, some physicians may require more or fewer cases
with a proctor depending on the experience, inherent skill
and personality of the physician, time elapsed between
cases, and other factors. Ultimately, the requirement for a
proctor being present or not is determined by Evasc in
consultation with the trainee physician and a proctor.
A Training Form documenting all of the above-mentioned
requirements is considered a record of the physician’s com-
pletion of training on the eCLIPs product.
Clinical follow-up
Clinical follow-up is the ultimate method to review not
only the training program but also the efficacy and safety
of the device. Follow-up must include patient status,
other clinical comorbidities, angiographic outcome, and
presence or absence of complications.
Evasc’s requirements for follow-up of eCLIPs implan-
tation include the following:
1) Patient neurologic status
2) Other procedure-related clinical morbidity/mortality
(e.g., bleeding)
3) Angiographic outcome
a. Raymond Score (17)
b. Evidence for device migration
c. Evidence for vessel trauma
4) All data are collected in either a prospective registry
or a prospective clinical trial
Results
Since 2013, with the first eCLIPs implantation under
Canada’s Special Access Program through CE Mark
approval in 2014, and through to July 31, 2016, Evasc’s
training program for the eCLIPs device has initiated
training for 23 neuro-interventionalists at 17 clinical sites.
This training has yielded 36 clinical implants at 13 sites
with no device-related complications (18). The clinical
efficacy of the eCLIPs device seems, in this early experi-
ence, to be favorable. Three proctors have participated in
the training program, in aggregate having implanted at
least 20 devices. Two clinical specialists have been trained.
Because the primary proctor (TRM) is based in
Toronto, Canada, travel has made it impossible to attend
cases in person in Europe in four instances. In these cases
(none the first attempted by the trainee), proctoring was
done via video Skype, with a clinical specialist in the
procedure room coordinating the communication between
the proctor and the trainee.
The decision to grant sign off on the Training Record,
indicating that the trainee has successfully completed the
training, has been made for six neurointerventionalists.
Feedback from the trainees, their clinical laboratory
staff, proctors, and clinical specialists has generally been
favorable and has resulted in a continuous quality im-
provement of the training manual and procedures.
Discussion
Creation and implementation of training modules for
the use of medical devices, their applications, and the
outcomes of training are not discrete requirements in
any regulatory approval process, such as the Medical
Device Directorate or the FDA. For example, the Council
Directive of the European Economic Community (EEC)
93/42/EEC (19) contains the rule that ‘each device must
be accompanied by the information needed to use it
safely and properly, taking account of the training and
knowledge of the potential users, and to identify the
manufacturer’. But the information is restricted to ‘the
details on the label and the data in the instructions for use’.
Donald R. Ricci et al.
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Thus, the onus is on the vendor or manufacturer to develop
fulsome training guidelines to be sure that the interven-
tionalist can apply the IFU within a step-by-step technical
framework.
Such formal and specific guidelines are typically effected
through the Risk Mitigation principles in a Quality
Systems doctrine (20). EN ISO 14971:2012 provides a
process for managing risks associatedwith medical devices.
A serious risk, of course, results from technical misuse
of the device, either because of failure to follow the IFU or
lack of knowledge of any nuances to the step-by-step
nature of its use, as distinguished from similar use devices.
Many interventionalists, because of their high level of
skill, large experience with the use of triaxial catheter
techniques, and/or extensive history with the use of
multiple new medical devices over a long period, become
inured to reading details of the IFU or perhaps, more
importantly, to assuming that use of a new device is
‘intuitive’. An excellent example of the cavalier attitude
to the detail of the IFU is the widespread use of devices
‘off label’, meaning they are being applied to solve a
problem for which the device was not explicitly designed
or approved. The FDA guidance on this matter suggests
that ‘if physicians use a product for an indication not
in the approved labeling, they have the responsibility
to be well informed about the product . . .’ (21) and
further asserts that ‘use of a marketed product in this
manner when the intent is the ‘‘practice of medicine’’’ is
appropriate, contingent on local ethics reviews or other
oversight. In the neurointerventional sphere, the use of
dual ‘Y- or T-stenting’ for management of bifurcation
aneurysms is probably the most notable use of a device
off-label to achieve a solution to a complex, otherwise
untreatable condition (22).
Interventional physicians should embrace the merits
of a training module to improve the user experience,
and vendors, the physicians, and the patients alike should
be aligned in the goal of device training to improve its
success rate and minimize complications of the procedure.
WHO has concluded that endovascular devices are
ideally suited for ‘virtual reality’ simulation training
such as that described herein over other methods such
as use of animal models (23). Our data cannot provide
information on the direct effect of device training upon
improved success or mitigation of complication with-
out an assessment of these effects in a cohort where no
training has occurred. The ethics of such a trial would
indeed be questionable. To suggest that training in the
use of a new interventional device is of value may, indeed,
be intuitive.
Conclusions
A formal device training program, containing multiple
elements, is a necessity for successful application of the
device to a clinical therapeutic procedure. Elements of a
generic program have been presented, exemplified by the
specific program for an innovative device developed for
the management of bifurcation intracranial aneurysms.
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